


AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions and listings of claims in the application:

LISTING OF CLAIMS:

1-6. (canceled).

7. (currently amended): A method for treatment of allergic conjunctivitis, eosinophilia, eosinophilic gastroenteritis, eosinophilic enteropathy, eosinophilic fasciitis, eosinophilic granuloma, eosinophilic pustular folliculitis, eosinophilic leukemia, and Acquired Immuno-Deficiency Syndrome (AIDS), comprising administering to a subject an effective amount of a compound having CCR3 antagonistic activity, wherein said compound is represented by the following formula (I), a pharmaceutically acceptable acid addition salt thereof, or a pharmaceutically acceptable C₁ to C₆ alkyl addition salt thereof,



wherein, R¹ represents ~~a naphthyl group, or~~ an aromatic heterocyclic group selected from the group consisting of an imidazolyl group, a pyrazolyl group, an oxazolyl group, an isoxazolyl group, a thiazolyl group, an isothiazolyl group, a pyrimidinyl group, a triazinyl group, a triazolyl group, an oxadiazolyl group, a thiadiazolyl group, a thienothienyl group, an indolyl group, a benzofuranyl group, a benzothienyl group, a quinolyl group, a benzimidazolyl group, a benzoxazolyl group, a benzotriazolyl group, a benzoxadiazolyl group, a benzothiadiazolyl group,

further provided that the naphthyl group or the aromatic heterocyclic group may be substituted by one or more halogen atoms, hydroxy groups, cyano groups, nitro groups, carboxyl groups, carbamoyl groups, C₁ to C₆ alkyl groups, C₃ to C₈ cycloalkyl groups, C₂ to C₆ alkenyl groups, C₁ to C₆ alkoxy groups, C₁ to C₆ alkylthio groups, C₃ to C₅ alkylene groups, C₂ to C₄ alkyleneoxy groups, C₁ to C₃ alkylendioxy groups, phenyl groups, phenoxy groups, phenylthio groups, benzyl groups, benzyloxy groups, benzoylamino groups, C₂ to C₇ alkanoyl groups, C₂ to C₇ alkoxycarbonyl groups, C₂ to C₇ alkanoyloxy groups, C₂ to C₇ alkanoylamino groups, C₂ to C₇ N-alkylcarbamoyl groups, C₄ to C₉ N-cycloalkylcarbamoyl groups, C₁ to C₆ alkylsulfonyl groups, C₃ to C₈ (alkoxycarbonyl)methyl groups, N-phenylcarbamoyl groups, piperidinocarbonyl groups, morpholinocarbonyl groups, 1-pyrrolidinylcarbonyl groups, divalent groups represented by the formula: -NH(C=O)O-, divalent groups represented by the formula: -NH(C=S)O-, amino groups, mono(C₁ to C₆ alkyl)amino groups or di(C₁ to C₆ alkyl)amino groups, and further provided that the substituents of the phenyl group, the C₃ to C₈ cycloalkyl group, the aromatic heterocyclic group or the condensed ring may further be substituted by one or more halogen atoms, hydroxy groups, amino groups, trifluoromethyl groups, C₁ to C₆ alkyl groups or C₁ to C₆ alkoxy groups;

R² represents a hydrogen atom, a C₁ to C₆ alkyl group, a C₂ to C₇ alkoxycarbonyl group, a hydroxy group or a phenyl group, provided that the C₁ to C₆ alkyl group or the phenyl group in R² may be substituted by one or more halogen atoms, hydroxy groups, C₁ to C₆ alkyl groups or C₁ to C₆ alkoxy groups, and provided that when j is 0, R² is not a hydroxy group;

~~j is represents an integer of 0 to 2;~~

k represents 0 or 1;

m represents an integer of 2 to 3;

n represents 0 or 1;

R³ represents a hydrogen atom or a C₁ to C₆ alkyl group which may be substituted by one or two phenyl groups which may be substituted by the same or different numbers of halogen atoms, hydroxy groups, C₁ to C₆ alkyl groups or C₁ to C₆ alkoxy groups;

R⁴ and R⁵, which may be the same or different, represent a hydrogen atom, a hydroxy group, a phenyl group or a C₁ to C₆ alkyl group, and the C₁ to C₆ alkyl group represented by R⁴ and/or R⁵ may be substituted by one or more halogen atoms, hydroxy groups, cyano groups, nitro groups, carboxyl groups, carbamoyl groups, mercapto groups, guanidino groups, C₃ to C₈ cycloalkyl groups, C₁ to C₆ alkoxy groups, C₁ to C₆ alkylthio groups, phenyl groups which may be substituted by one or more halogen atoms, hydroxy groups, C₁ to C₆ alkyl groups, C₁ to C₆ alkoxy groups or benzyloxy groups, phenoxy groups, benzyloxy groups, benzyloxycarbonyl groups, C₂ to C₇ alkanoyl groups, C₂ to C₇ alkoxycarbonyl groups, C₂ to C₇ alkanoyloxy groups, C₂ to C₇ alkanoylamino groups, C₂ to C₇ N-alkylcarbamoyl groups, C₁ to C₆ alkylsulfonyl groups, amino groups, mono(C₁ to C₆ alkyl)amino groups, di(C₁ to C₆ alkyl)amino groups or aromatic heterocyclic groups (having one to three atoms of oxygen, sulfur and/or nitrogen as heteroatoms), or condensed rings formed by the condensation of the aromatic heterocyclic group with a benzene ring, or R⁴ and R⁵ may together form a three to six-membered cyclic hydrocarbon;

p represents 0 or 1;

q represents 0 or 1;

G represents a group represented by $-NR^7-CO-$, $-NH-CO-NH-$, or $-NH-CS-NH$ provided that R^7 is a hydrogen atom ;

R^6 represents a phenyl group, a C_3 to C_8 cycloalkyl group, a C_3 to C_6 cycloalkenyl group, a benzyl group or an aromatic heterocyclic group having one to three atoms of oxygen, sulfur and/or nitrogen as heteroatoms, provided that the phenyl group, the benzyl group or the aromatic heterocyclic group represented by R^6 may be condensed, to make a condensed ring, with a benzene ring or an aromatic heterocyclic group having one or three atoms of oxygen, sulfur and/or nitrogen as heteroatoms, further provided that the phenyl group, the C_3 to C_8 cycloalkyl group, the C_3 to C_6 cycloalkenyl group, the benzyl group, the aromatic heterocyclic group or the condensed ring represented by R^6 may be substituted by one or more halogen atoms, hydroxy groups, mercapto groups, cyano groups, nitro groups, thiocyanato groups, carboxyl groups, carbamoyl groups, trifluoromethyl groups, C_1 to C_6 alkyl groups, C_3 to C_6 cycloalkyl groups, C_2 to C_6 alkenyl groups, C_1 to C_6 alkoxy groups, C_3 to C_8 cycloalkyloxy groups, C_1 to C_6 alkylthio groups, C_1 to C_3 alkylenedioxy groups, phenyl groups, phenoxy groups, phenylamino groups, benzyl groups, benzoyl groups, phenylsulfinyl groups, phenylsulfonyl groups, 3-phenylureido groups, C_2 to C_7 alkanoyl groups, C_2 to C_7 alkoxycarbonyl groups, C_2 to C_7 alkanoyloxy groups, C_2 to C_7 alkanoylamino group, C_2 to C_7 N-alkylcarbamoyl groups, C_1 to C_6 alkylsulfonyl groups, phenylcarbamoyl groups, N,N-di(C_1 to C_6 alkyl)sulfamoyl groups, amino groups, mono(C_1 to C_6 alkyl)amino groups, di(C_1 to C_6 alkyl)amino groups, benzylamino groups, C_2 to C_7 (alkoxycarbonyl)amino groups, C_1 to C_6 (alkylsulfonyl)amino groups or bis(C_1 to C_6

alkylsulfonyl)amino groups, and further provided that the substituents of the phenyl group, the C₃ to C₈ cycloalkyl group, the C₃ to C₈ cycloalkenyl group, the benzyl group, the aromatic heterocyclic group, or the condensed ring may further be substituted by one or more halogen atoms, cyano groups, hydroxy groups, amino groups, trifluoromethyl groups, C₁ to C₆ alkyl groups, C₁ to C₆ alkoxy groups, C₁ to C₆ alkylthio groups, mono(C₁ to C₆ alkyl)amino groups, or di(C₁ to C₆ alkyl)amino groups; and

wherein when k is 1 and m is 2, then n is 0; and

wherein m + k is 3.

8-10. (canceled).

11. (previously presented): The method according to Claim 7, wherein the disease treatable by administration of a CCR3 antagonist is AIDS.

12. (previously presented): The method according to Claim 7, wherein k is 1 and m is 2 in said formula (I).

13. (previously presented): The method according to Claim 7 or 11, wherein n is 0 in said formula (I).